Participating Companies

4SC AG [VSC:DB] €31 MM MCap
An epi­ge­net­ic fo­cused com­pany de­vel­op­ing small molecule drugs for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany’s lead com­pound, Res­mi­no­s­tat, is fo­cused on Cu­ta­neous T Cell Lym­pho­ma but has un­part­nered as­sets for Hod­kins Lym­pho­na, Col­orec­tal Can­cer, and HCC. [more in­for­ma­tion]
Ability Pharmaceuticals, SL
ABTL0812 has been grant­ed Or­phan Drug Desig­na­tion (ODD) for neu­roblas­to­ma, pan­cre­at­ic can­cer and for biliary tract can­cer by FDA and EMA, and the drug has a sales po­ten­tial over &eu­ro;2.5 bil­lion in 2025, with a mar­ket share over 80% in se­lect­ed can­cer types. [more in­for­ma­tion]
Abliva Ab [ABLI:ST] SKr210 MM MCap
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
Active Biotech AB [ATVBY]
Ac­tive Biotech AB fo­cus­es on the re­search and de­vel­op­ment of phar­ma­ceu­ti­cals prod­ucts within med­i­cal ar­eas in­clud­ing can­cer and in­flam­ma­to­ry dis­eas­es. Its pro­ject port­fo­lio con­tains both small molecules that are oral­ly ac­tive im­muno­mo­d­u­la­to­ry agents and anti­body based im­munother­a­py. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod® plat­forms. Lead can­di­date ABY-035 is an IL-17 with mul­ti­ple Ph 2 pro­grams (PSO OLE PsA, axS­pA, uvei­tis). Pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis with 2-yr OLE da­ta ex­pect­ed in 2H21. Ph2 in­ter­im da­ta for uvei­tis ex­pect­ed in 2022. AB-251 is a di­ag­nos­tic imag­ing pro­gram that is di­rect­ed pri­mar­i­ly to­wards me­tastat­ic breast can­cer. $81M raised to date. [more in­for­ma­tion]
AgomAb Therapeutics
Our grow­ing pipe­line of high­ly spe­cif­ic mon­o­clo­n­al anti­bodies is de­signed to treat a range of acute and chron­ic con­di­tions that in­volve in­flam­ma­to­ry, metabolic and fi­brot­ic pro­cess­es. By com­bin­ing new sci­en­tif­ic in­sights with ro­bust de­vel­op­ment ex­per­tise, we are build­ing a com­pany to lead to the emer­gence of tru­ly re­gen­er­a­tive medicines. [more in­for­ma­tion]
AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
Bachem Holding AG [BANB:SM] SwF7,460 MM MCap
Bachem is a lead­ing and in­no­va­tion-driv­en com­pany spe­cial­iz­ing in the de­vel­op­ment and man­u­fac­ture of pep­tides and oli­gonu­cleotides. Head­quar­tered in Switz­er­land and with lo­ca­tions in Eu­rope, the USA and Asia, Bachem op­er­ates in­ter­na­tio­n­al­ly and has 50 years of ex­pe­ri­ence and ex­per­tise that is unique in the in­dus­try. [more in­for­ma­tion]
Basilea Pharmaceutica Ltd [BSLN:SM] SwF513 MM MCap
is a com­mer­cial stage bio­phar­ma­ceu­ti­cal com­pany, fo­cused on the de­vel­op­ment of prod­ucts that ad­dress the med­i­cal chal­lenges in the ther­a­peu­tic ar­eas of on­col­o­gy and an­ti-in­fec­tives. [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr7,051 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for im­proved Q of life, treat­ment out­comes and re­source uti­l­iza­tion. [more in­for­ma­tion]
Cantargia AB [CANTA:ST] SKr1,559 MM MCap
The ba­sis for this is the pro­tein IL1RAP that is in­volved in a num­ber of dis­eas­es and where Can­tar­gia has estab­lished a plat­form. Can­tar­gia's other pro­ject, CAN10, is in the pre­clin­i­cal phase and is aim­ing to de­vel­op an IL1RAP bind­ing anti­body block­ing IL-1, IL-33 and IL-36 - op­ti­mised for the treat­ment of sys­temic scle­ro­sis and my­o­cardi­tis. [more in­for­ma­tion]
Cellestia Biotech AG
Celles­tia Biotech AG is a pri­vate­ly-owned clin­i­cal-stage com­pany de­vel­op­ing in­no­va­tive first-in-class ther­a­pies to con­trol and mo­d­u­late patho­genic gene ex­pres­sion in mul­ti­ple dis­ease ar­eas by se­lec­tive in­hi­bi­tion of tran­scrip­tion fac­tors in the cell nu­cleus. [more in­for­ma­tion]
Corwave
De­vel­op­er of in­no­va­tive im­plant­ed car­di­ac sup­port de­vices de­signed for pa­tients suf­fer­ing from heart fail­ure. The com­pany's de­vice con­sists of an im­plantable heart pump based on wave mem­brane pump­ing tech­nol­o­gy and us­es an os­cil­lat­ing mem­brane to dis­place fluid, en­abling pa­tients to suf­fer from few­er com­pli­ca­tions and re­duce the pain and bur­den from in­va­sive surgery. [more in­for­ma­tion]
COSMO Pharmaceuticals N.V. [C43.F]
Cos­mo is a spe­cial­ty phar­ma­ceu­ti­cal com­pany fo­cused in treat­ing se­lect­ed Gas­troin­testi­nal Di­s­or­ders. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
Ellipses Pharma
El­lips­es Phar­ma is fo­cused ex­clu­sive­ly on the de­vel­op­ment of in­no­va­tive can­cer medicines and treat­ments. Our mis­sion is to make the very best drugs and ther­a­pies avai­l­able to pa­tients at an un­prece­dent­ed speed through our per­ma­nent, fixed source of fund­ing that al­lows us to speed up de­vel­op­ment and own more of the val­ue chain. [more in­for­ma­tion]
Enterome
En­terome is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing nov­el drugs based on its unique abil­i­ty to de-code molec­u­lar in­ter­ac­tions in the gut mi­cro­biome im­pact­ing hu­man health. En­terome’s suc­cess is based on its unique abil­i­ty to iden­ti­fy small pro­teins and pep­tides from gut bac­te­ria that can de­liv­er a ther­a­peu­tic ben­e­fit in hu­mans. [more in­for­ma­tion]
eTheRNA immunotherapies
The com­pany's im­munother­a­pies con­tain pro­pri­e­tary mR­NA-based TriM­ix tech­nol­o­gy that boosts den­drit­ic cells lead­ing to a more com­pre­hen­sive, sus­tain­able, and safer en­hance­ment of the pa­tient's im­mune sys­tem than any other sim­i­lar ap­proach in­vesti­gat­ed, en­abling health­care providers to help pa­tients fight can­cer and other in­fec­tious dis­eas­es. [more in­for­ma­tion]
Ethris GmbH
We are rapid­ly ap­proach­ing in vi­vo proof of con­cept for gen­er­at­ing ther­a­peu­tic anti­bodies against COVID-19 in the lung through a part­nered pro­gram while ad­vanc­ing our pipe­line of im­muno-mo­d­u­la­tion and mR­NA-based pro­tein re­place­ment ther­a­pies with the ul­ti­mate goal of im­prov­ing pa­tients’ lives [more in­for­ma­tion]
Evotec AG [EVTA:FF] $6,017 MM MCap
The EVT In­no­vate seg­ment is an in­ter­nal drug dis­cov­ery plat­form with over 70 prod­uct op­por­tu­ni­ties and ex­per­tise across dis­eas­es ar­eas. [more in­for­ma­tion]
Eyevensys
Eye­ven­sys cre­ates oph­thalmic ther­a­peu­tic bio fac­to­ries to sus­tain­ab­ly treat ma­jor eye dis­eas­es. [more in­for­ma­tion]
Faron Pharmaceuticals [4FR:FF] €30 MM MCap
Cleve­g­en (bex­mar­il­imab), its in­vestiga­tive pre­ci­sion im­munother­a­py in phase I/II de­vel­op­ment as a nov­el macrophage check­point im­munother­a­py for pa­tients with un­treat­able solid tu­mours, is a nov­el an­ti-Clev­er-1 anti­body with the abil­i­ty to switch im­mune sup­pres­sion to im­mune ac­ti­va­tion. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €145 MM MCap
AT­AC plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. Lead prod­uct HDP-101, for blood can­cer, is ex­pect­ed to start clin­i­cal dev' end of 2021. Out-li­cens­ing the AT­AC tech­nol­o­gy us­ing the part­n­ers’ anti­bodies to cre­ate new AT­ACs and ex­pect long term in­come streams and ear­ly tech­nol­o­gy vali­da­tion. [more in­for­ma­tion]
HepaRegeniX
He­paRe­geniX is de­vel­op­ing nov­el ther­a­pies for the treat­ment of acute and chron­ic liv­er dis­eas­es. Since its start in 2017, He­paRe­geniX has suc­cess­ful­ly dis­cov­ered and de­vel­oped sev­er­al pre­clin­i­cal drug can­di­dates for the treat­ment of acute and chron­ic liv­er dis­eas­es based on a nov­el pro­pri­e­tary molec­u­lar tar­get Mi­to­gen-Ac­ti­vat­ed Pro­tein (MAP) Ki­nase Ki­nase 4 (MKK4). [more in­for­ma­tion]
Horama
HO­RA­MA’s ap­proach is based on vec­tor tech­nol­o­gy us­ing non-patho­genic, re­com­bi­nant ade­no-as­so­ci­at­ed virus­es (rAAV) and new gen­er­a­tion of mod­i­fied rAAV (mrAAV). V-Bio, Turenne Cap­i­tal, Id­In­vest Part­n­ers, GO Cap­i­tal, Sham In­no­va­tion Sant&ea­cute; and Omnes Cap­i­tal al­so par­ti­ci­pat­ed in the round. [more in­for­ma­tion]
Imcyse
De­vel­op­ing dis­ease spe­cif­ic im­mune ther­a­pies to treat se­vere, chron­ic au­to-im­mune, in­flam­ma­to­ry, al­ler­g­ic, in­fec­tious dis­eas­es and tu­mors. [more in­for­ma­tion]
Immune Regulation Ltd
Th­ese ther­a­pies ex­hib­it a short phar­ma­coki­net­ic ac­tiv­i­ty but re­set the im­mune sys­tem from a pro-in­flam­ma­to­ry to a reg­u­la­to­ry state to in­duce long-term dis­ease re­mis­sion in pa­tients with al­ler­g­ic and im­mune me­di­at­ed dis­eas­es, with­out the neg­a­tive ef­fects of chron­ic cur­rent ther­a­pies. [more in­for­ma­tion]
Immunicum AB [IMMU:ST] SKr633 MM MCap
With com­ple­men­tary ther­a­peu­tic ap­proach­es in Phase II clin­i­cal de­vel­op­ment that are based on in­tra­tu­mo­ral prim­ing and can­cer re­lapse vac­ci­na­tion, the com­pany aims to im­prove sur­vi­val out­comes and qual­i­ty of life for a broad pop­u­la­tion of can­cer pa­tients. Based in Swe­den and the Nether­lands, Im­mu­nicum is publi­c­ly trad­ed on the Nas­daq Stock­holm. [more in­for­ma­tion]
InteRNA Technologies
The trig­ger­ing of the im­muno­genic tu­mor cell death (ICD) pro­cess as well as down­reg­u­la­tion of the adeno­sine-A2A re­cep­tor path­way through in­hi­bi­tion of CD39/CD73 leads to a de­crease in im­muno­sup­pres­sive Fox­P3/Lag3 reg­u­la­to­ry T cells and mono­cyt­ic myeloid-de­rived sup­pres­sor cells (mMD­SCs), and ma­t­u­ra­tion of den­drit­ic cells. [more in­for­ma­tion]
KAHR
KAHR is de­vel­op­ing nov­el im­muno-on­col­o­gy fu­sion pro­teins. DSP107, is a CD47-41BB tar­get­ing com­pound aimed at tar­get­ing can­cer cells' in­nate de­fens­es and ac­ti­vat­ing lo­cal­ized re­sponse. Ac­ti­vat­ed path­ways in­clude in­nate and adap­tive im­mu­ni­ty. [more in­for­ma­tion]
Kiadis Pharma N.V. [KDS-AMS]
NK-cell plat­form ad­min­is­tered as ad­junct I-O on top of HSCT. Launched FIH POC trial in r/r AML pa­tients (Feb 2020); set to launch ad­di­tio­n­al HSCT trial lat­er in 2020 w/in­ter­im da­ta exp 2021. Pre­sent­ing new da­ta on ex-vi­vo FC21 ex­pand­ed NK-cell ther­a­py in 13 pa­tients at EBMT in 2020. Estab­lished POC in 37 pa­tients to­tal. [more in­for­ma­tion]
MC2 Therapeutics
Us­ing our nov­el PAD™ Tech­nol­o­gy as a corn­er­s­tone of our top­i­cal for­mu­la­tions we de­vel­op in­no­va­tive best-in-class or first-in-class top­i­cal ther­a­pies tailored for fast and safe re­lief of symp­toms in for­mu­la­tions that pa­tients pre­fer to use in dai­ly routines. [more in­for­ma­tion]
MiNA Therapeutics
Ver­satile, pro­pri­e­tary small ac­ti­vat­ing ri­bonu­cle­ic acid (saR­NA) ther­a­peu­tics plat­form and in­ter­nal pipe­line, ini­tial­ly fo­cus­ing on on­col­o­gy and rare dis­ease in­di­ca­tions. Ini­ti­at­ing ran­domized Ph2 study for lead saR­NA drug can­di­date MTL-CEB­PA com­bined with so­rafenib in 2L HCC in 1Q22. Ph1b read­out in solid tu­mors (MTL-CEB­PA+Pem­bro PD-1) in 1Q22. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, lerigl­i­ta­zone, de­mon­s­trat­ed clin­i­cal ben­e­fit of sig­ni­f­i­cant­ly re­duc­ing pro­gres­sion of cere­bral le­sions and myelo­pa­thy symp­toms in piv­o­tal Phase 2/3 study re­sults in X-ALD pts w Adreno­myeloneu­ro­pa­thy (AMN), 6MWT end­point was not met; on­go­ing dis­cus­sions with reg­u­la­tors re: ap­pro­val. Phase 2 da­ta in Frie­drich’s Ataxia showed mo­d­u­la­tion of the Fra­taxin path­way and res­to­ra­tion of the bioen­er­get­ics de­fic­its in FR­DA pa­tients. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Mitotech
Com­pany's lead com­pound SkQ1 is be­ing de­vel­oped in sev­er­al drug for­mu­la­tions cov­er­ing a va­ri­e­ty of ther­a­peu­tic ar­eas with ma­jor fo­cus on oph­thal­mol­o­gy and neu­rode­gen­er­a­tive dis­eas­es. In VIS­TA-1 – a Phase 2b/3 clin­i­cal study in the Unit­ed States (NC­T03764735) - SkQ1 showed evi­dence of ef­fi­ca­cy in re­duc­ing both the signs and symp­toms in Dry Eye sub­jects. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Lead prod­uct, icos­abu­tate has been found safe and ef­fec­tive in two pri­or phase 2 clin­i­cal studies for treat­ment of hy­per­trig­lyc­eridemia and mixed dys­lipi­demia and is cur­rent­ly in clin­i­cal de­vel­op­ment for NASH. The icos­abu­tate phase 2b ICO­NA NASH trial is sche­d­uled to read­out in the first quar­ter of 2023. Two ad­di­tio­n­al SE­FAs are in clin­i­cal de­vel­op­ment; SE­FA 1024 is in phase 1 to be de­vel­oped for dys­lipi­demia and SE­FA 6179, [more in­for­ma­tion]
Nouscom AG
Nous­com is a next-gen­er­a­tion im­munother­a­py com­pany de­vel­op­ing ge­net­ic neoanti­gen vaccines and on­co­lyt­ic virus­es for pre­ven­tion and treat­ment of can­cer. The com­pany has of­fices in Basel and Rome. [more in­for­ma­tion]
Oncimmune [ONC:LN]
Oncim­mune has a di­ver­si­fied and grow­ing rev­enue from its port­fo­lio of di­ag­nos­tic prod­ucts to de­tect ear­ly-stage can­cer and a con­tract dis­cov­ery and de­vel­op­ment ser­vice-based plat­form, de­liv­er­ing ac­tion­able in­sights in­to ther­a­pies to its phar­ma­ceu­ti­cal and biotech part­n­ers. [more in­for­ma­tion]
Oxurion [OXUR:BR] €63 MM MCap
Ox­u­ri­on is aim­ing to build the lead­ing glob­al franchise in the treat­ment of DME, based on the suc­cess­ful de­vel­op­ment of its two nov­el ther­a­peu­tics: • THR-149, a plas­ma kal­likrein in­hibi­tor be­ing de­vel­oped as a po­ten­tial new stan­dard of care for DME pa­tients who re­spond sub-op­ti­mal­ly to an­ti-VEGF ther­a­py. [more in­for­ma­tion]
PCI Biotech AS [PCIB:OS] NKr194 MM MCap
fi­maCHEM which is an en­hance­ment of che­mother­a­peu­tics for lo­cal­ized treat­ment of can­cer, fi­ma­VACC which is T-cell in­duc­tion tech­nol­o­gy for ther­a­peu­tic vac­ci­na­tion, and fi­maNAc which is nu­cle­ic acid ther­a­peu­tics de­liv­ery. The op­er­at­ing seg­ment of the group is Re­search and de­vel­op­ment. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €501 MM MCap
re­cent in-li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing COVID-19, pre-eclamp­sia, AKI and ad­di­tio­n­al pipe­line prod­uct from tech­nol­o­gy plat­form: re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr2,363 MM MCap
Rev­enue-gen­er­at­ing urol­o­gy-fo­cused com­pany. Lead prod­uct, Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC), which can re­duce dis­ease re­cur­rence and pro­gres­sion rates. Hexvix®/Cysview® is in­clud­ed in clin­i­cal consen­sus guide­lines and re­mains on a strong growth path. Rev­enues in 2020 to­taled $31M. Re­cent­ly suc­cess­ful­ly launched the Eu­ro­pean Hexvix op­er­a­tions, con­soli­dat­ing the Com­pany’s prod­uct franchise glob­al­ly. [more in­for­ma­tion]
Precirix
PRE­CIR­IX® is a clin­i­cal-stage biotech­nol­o­gy com­pany ded­i­cat­ed to im­prov­ing the lives of can­cer pa­tients by de­vel­op­ing nov­el tar­get­ed ra­dio­phar­ma­ceu­ti­cals us­ing camelid sin­gle do­main anti­body frag­ments. The com­pany is ad­vanc­ing its lead prod­uct CAM-H2 through a Phase I/II clin­i­cal trial tar­get­ing HER2-pos­i­tive tu­mors, while fur­ther pro­gress­ing and broa­d­en­ing its on­col­o­gy pipe­line. [more in­for­ma­tion]
Prilenia
Prile­nia is a clin­i­cal stage biotech com­pany, led by Michael Hay­den, MD, PhD., to­gether with a high­ly ex­pe­ri­enced team with a track re­cord of suc­cess. Michael is a world-renowned sci­en­tist in Hunt­ing­ton Dis­ease re­search. He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. The com­pany has re­cent­ly raised $68.5M in a Se­ries A fi­nanc­ing round to launch [more in­for­ma­tion]
PROSION
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
De­vel­op­er of tar­get­ed on­col­o­gy ther­a­pies in­clud­ing he­ma­tol­o­gy/solid tu­mors. RVU120 is whol­ly-owned first-in-class oral CD­K8/19 in­hibi­tor in Phase I for AML/MDS Small molecule, syn­thet­ic lethal­i­ty plat­form in pre-clin­i­cal de­vel­op­ment in­clud­ing nov­el tar­gets WRN and PRMT5. [more in­for­ma­tion]
Sensorion [ALSEN]
Its clin­i­cal-stage port­fo­lio in­cludes one Phase 2 prod­uct: SEN­S401 (Araza­setron) for sud­den sen­sorineu­ral hear­ing loss (SSNHL).Sen­so­ri­on has launched three gene ther­a­py pro­grams, cur­rent­ly at pre­clin­i­cal stage, aimed at cor­rect­ing hered­i­tary mono­genic forms of deaf­ness in­clud­ing deaf­ness caused by a mu­ta­tion of the gene en­cod­ing for Otofer­lin, hear­ing loss re­lat­ed to gene tar­get GJB2 as well as Ush­er Syn­drome Type 1 to po­ten­tial­ly ad­dress im­por­tant hear­ing loss seg­ments in adults and chil­dren. [more in­for­ma­tion]
Sensyne Health [SENS] $961 MM MCap
It is de­vel­op­ing soft­ware prod­ucts and con­duct­ing med­i­cal re­search, us­ing ma­chine learn­ing, to im­prove pa­tient care and ac­cel­er­ate the de­vel­op­ment of new treat­ments. [more in­for­ma­tion]
SNIPR BIOME
Op­er­a­tor of a dis­cov­ery stage biotech com­pany in­tend­ed to rev­o­lu­tion­ize the treat­ment of mi­cro­bial dis­eas­es. The com­pany us­es CRIS­PR tech­nol­o­gy that can sub­vert el­e­ments of the en­doge­nous bac­te­rial CRIS­PR machin­ery to elim­i­nate hazar­dous bac­te­ria in vi­vo, pro­vid­ing the health pro­fes­sio­n­als with medicines that se­lec­tive­ly tar­get and kill bac­te­ria with spe­cif­ic DNA se­quences. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Theravectys
Ad­di­tio­n­al­ly, the com­pany will be us­ing their nov­el T cell vaccine plat­form tech­nol­o­gy to ad­vance the de­vel­op­ment of their prod­uct can­di­dates in HPV in­duced can­cers in­to clin­i­cal trials. [more in­for­ma­tion]
Treos Bio Limited
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
Vaximm AG
The com­pany's oral T-cell im­munother­a­py vaccines are based on first-in-class oral T-cell ac­ti­va­tors that us­es mod­i­fied at­ten­u­at­ed bac­te­ria that can be read­i­ly adapt­ed to tar­get a wide range of can­cer-re­lat­ed anti­gens, en­abling can­cer pa­tients to get ad­vanced treat­ment for quick re­cov­ery of their di­s­or­ders. [more in­for­ma­tion]
Versantis
Ver­san­tis is a phase 2a phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of or­phan medicines to rev­o­lu­tion­ize the care of pa­tients with liv­er dis­eas­es. Ver­san­tis is de­vel­op­ing its lead can­di­date, VS-01, as a first-line med­i­ca­tion for the acute sup­port of cir­rhot­ic and metabolic de­com­pen­sa­tions. VS-01 re­ceived Or­phan Drug desig­na­tion from both FDA and EMA. [more in­for­ma­tion]
Vico Therapeutics BV
Vi­co Ther­a­peu­tics is a Lei­den, the Nether­lands, based biotech com­pany fo­cus­ing on the de­vel­op­ment of RNA mo­d­u­lat­ing ther­a­pies for rare se­vere neu­ro­log­i­cal di­s­or­ders. Vi­co’s an­ti­sense oli­gonu­cleotide plat­form (AON) is fo­cus­ing on dif­fer­ent forms of Spino­cere­bel­lar Ataxia (SCA) and Hunt­ing­ton Dis­ease (HD). [more in­for­ma­tion]
Vicore Pharma [VICO:ST] SKr990 MM MCap
1) A phase II ran­domized, dou­ble-blind, place­bo-con­trolled study with C21 in COVID-19 pa­tients showed strong clin­i­cal ef­fi­ca­cy sig­nals, 2) A mech­anis­tic phase II study with C21 in pa­tients with Ray­naud's pheno­m­e­na in sys­temic scle­ro­sis showed va­sodi­la­tion of re­sis­tance ves­sels in fi­brot­ic tis­sue, and 3) C21 re­duced TGF-be­ta up­reg­u­la­tion in IPF lung slices. [more in­for­ma­tion]
Vivoryon [VVY:AS] €256 MM MCap
Fo­cused on nov­el small molecule in­hibi­tors of glu­taminyl cy­clase (QPCT) de­signed to pre­vent the for­ma­tion of patho­log­i­cal­ly al­tered pro­teins be­fore they cause ir­re­v­ersi­ble da­m­age. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in Phase 2 in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD. [more in­for­ma­tion]